APA

Rafii S., Gourley C., Kumar R., Geuna E., Ern Ang J., Rye T., Chen L., Shapira-Frommer R., Friedlander M., Matulonis U., De Greve J., Oza A. M., Banerjee S., Molife L. R., Gore M. E., Kaye S. B. & Yap T. A. (20180423). Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. : Oncotarget.

Chicago

Rafii Saeed, Gourley Charlie, Kumar Rajiv, Geuna Elena, Ern Ang Joo, Rye Tzyvia, Chen Lee-May, Shapira-Frommer Ronnie, Friedlander Michael, Matulonis Ursula, De Greve Jacques, Oza Amit M, Banerjee Susana, Molife L Rhoda, Gore Martin E, Kaye Stan B and Yap Timothy A. 20180423. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. : Oncotarget.

Harvard

Rafii S., Gourley C., Kumar R., Geuna E., Ern Ang J., Rye T., Chen L., Shapira-Frommer R., Friedlander M., Matulonis U., De Greve J., Oza A. M., Banerjee S., Molife L. R., Gore M. E., Kaye S. B. and Yap T. A. (20180423). Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. : Oncotarget.

MLA

Rafii Saeed, Gourley Charlie, Kumar Rajiv, Geuna Elena, Ern Ang Joo, Rye Tzyvia, Chen Lee-May, Shapira-Frommer Ronnie, Friedlander Michael, Matulonis Ursula, De Greve Jacques, Oza Amit M, Banerjee Susana, Molife L Rhoda, Gore Martin E, Kaye Stan B and Yap Timothy A. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. : Oncotarget. 20180423.